Press release
Rising Migraine Incidence Fuels Growth Of Aimovig Market: A Key Factor Shaping the Future of the Aimovig Market in 2025
Aimovig Market
The prevalence of migraines is on the rise, setting the trajectory for the growth of the aimovig market. These complex neurological disorders, marked by repetitive headaches and associated with symptoms like nausea, light and sound sensitivity, can be attributed to lifestyle changes, escalating stress levels, genetic predisposition, hormonal shifts (especially in women), and heightened diagnostic awareness, among others. Aimovig, a trailblazer as the first FDA-approved CGRP receptor blocker, caters to the lack of suitable treatments for such disorders. With its AI-enabled algorithms, aimovig platform paves new ways for migraine management by tracking, analyzing, and forecasting migraines triggers. Personalized suggestions for prevention and symptom reprieve along with live management driven by data-backed insights, contribute to lessening the frequency, intensity, and duration of migraine episodes while also enhancing overall life quality. For context, the House of Commons Library revealed in March 2024 that nearly 10 million UK inhabitants suffer from migraines. Hence, it's fair to say that the surge in migraines has been aiding the expansion of the aimovig market. The upsurge in healthcare expenditure is anticipated to spur further acceleration in the aimovig market. This spending encompasses the collective financial resources dedicated by individuals, institutions, private insurers, and other entities for healthcare services and product delivery. The augmented spending in healthcare can be tied down to an aging population, medical technological advancements, elevating rates of chronic ailments, and an amplified demand for healthcare amenities. It bolsters aimovig by promoting investments in novel treatments, extending patient accessibility via insurance coverages, subsidizing continuous research for better therapeutic results, and advocating public health schemes that amplify awareness and adoption of migraine preventive therapies. Evidence of this comes from the Office for National Statistics' May 2024 report, which stated that the British healthcare spent grew by 5.6% between 2022 and 2023, contrasting with the 0.9% growth in 2022, with the total expenditure coming to $317.63 billion (£292 billion) in 2023. Therefore, an increase in healthcare expenditure lines up with the increased robustness of the aimovig market.
Get Your Aimovig Market Report Here:
https://www.thebusinessresearchcompany.com/report/aimovig-global-market-report
What is the projected compound annual growth rate (CAGR) of the aimovig market from 2025 to 2034, and what factors influence it?
The growth in the Aimovig market, which has seen an increase of XX (HCAGR) in recent times, is projected to escalate from $XX million in 2024 to $XX million in 2025, with a CAGR of XX%. This surge during the historic period is due to various factors such as an increased occurrence of migraine disorders, progress in CGRP (calcitonin gene-related peptide) research, a rising need for specified migraine therapies, an elevated acknowledgment of chronic migraine as a neurological ailment, endorsing regulatory approvals for migraine treatments, broader access to healthcare and improved infrastructure, coupled with amplified investment in biotechnology for ground-breaking treatments.
Over the next few years, the aimovig market size is anticipated to reach XX (FCAGR). By 2029, it's projected to climb to $XX million, with a compound annual growth rate (CAGR) of XX%. Factors contributing to this expansion in the forecast period include increased instances of chronic migraines, ongoing advancements in CGRP inhibitors, growing use of Aimovig as a premier treatment for preventing migraines, augmenting clinical proof of Aimovig's effectiveness, a surge in demand for non-daily migraine solutions, a rise in healthcare expenditure on neurologic disorders, and broader insurance coverage for migraine treatments. Key trends anticipated for the forecast period encompass rising use of CGRP inhibitors, the development of more user-friendly delivery systems such as self-administered injections, the utilization of cutting-edge monitoring technologies for individualized treatment, burgeoning collaborations between biotech companies and healthcare providers, an increased emphasis on personalized migraine treatments, and market penetration in emerging regions with significant unmet medical requirements.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19866&type=smp
What are the major segments of the aimovig market and their role in driving growth?
The aimovigmarket covered in this report is segmented -
1) By Clinical Indication: Migraine; Cluster Headache; Other Headache Disorders
2) By Distribution Channel: Hospital And Clinics; Retail And Specialty Pharmacies
3) By End User: Adult; Geriatric
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/Discount?id=19866&type=discount
Which regions are key players in the growth of the aimovig market?
North America was the largest region in the aimovig market in 2024. The regions covered in the aimovig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the key firms paving the way for growth in the aimovig market?
Major companies operating in the aimovig market include Novartis AG, Amgen Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=19866&type=smp
What Is Covered In The Aimovig Global Market Report?
•Market Size Forecast: Examine the aimovig market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the aimovig market for a structured understanding.
•Key Players Overview: Analyze major players in the aimovig market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the aimovig market.
•Segment Contributions: Evaluate how different segments drive overall growth in the aimovig market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the aimovig market.
•Industry Challenges: Identify potential risks and obstacles affecting the aimovig market.
•Competitive Landscape: Review strategic developments in the aimovig market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Migraine Incidence Fuels Growth Of Aimovig Market: A Key Factor Shaping the Future of the Aimovig Market in 2025 here
News-ID: 3937533 • Views: …
More Releases from The Business Research Company
Global Dermal Regeneration Market Expansion at 8.9% CAGR, Valued at $2.52 Billio …
"Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
What Are the Dermal Regeneration Market Size Forecast for 2025?
In recent years, the market size of dermal regeneration has significantly expanded. Its growth is set to continue, moving from a market value of $1.64 billion in 2024, surging to $1.79 billion in 2025, indicating a Compound Annual Growth Rate…
Dental Emergency Kit Market Expansion Outlook: $1.74 Billion in 2029
"Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Projected CAGR for the Dental Emergency Kit Market from 2024 to 2025?
In recent times, the dental emergency kit market has seen significant growth. Projected growth rates suggest an increase from $1.18 billion in 2024 to $1.28 billion in 2025, manifesting a compound annual growth rate (CAGR) of 8.2%.…
Cryopreservation Equipment Industry Growth Outlook: 15.4% CAGR and $19.55 Billio …
"Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Long-Term Growth Forecast for the Cryopreservation Equipment Market Size 2025?
The expansion of the cryopreservation equipment market has been significant in recent years. The market which is expected to escalate from $9.52 billion in 2024 to $11.01 billion in 2025, will do so with a compound annual growth rate…
Connected Wearable Patches Industry to Achieve $10.78 Billion Growth by 2029
"Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
How Will the Connected Wearable Patches Market Grow by 2025 in Terms of Size and Growth?
The market size for connected wearable patches has seen significant expansion in the most recent years. With an expected rise from $5.62 billion in 2024 to $6.42 billion in 2025, representing a compound annual growth rate…
More Releases for Aimovig
Aimovig Industry Report 2025-2034: Market Dynamics, Drivers, And Forecasts
The Aimovig Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Aimovig Market Size During the Forecast Period?
In the recent past, the aimovig market, with its size of XX (HCAGR), has demonstrated significant growth. It's projected to rise from $XX million in…
Migraine Market on Track for Major Expansion by 2034, According to DelveInsight …
The Key Migraine Companies in the market include - Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others.
The Migraine market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage…
Key Driver Reshaping the Aimovig Market in 2025: Rising Migraine Incidence Fuels …
What Are the Projections for the Size and Growth Rate of the Aimovig Market?
The growth in size of the aimovig market has been consistently at $XX in recent years. It's predicted that the market will expand from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of $XX%. Several factors account for the historical growth, including increasing occurrence of migraine disorders, breakthroughs in…
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by Delve …
The Key Migraine Companies in the market include - Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others.
The Migraine market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage…
Migraine Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | …
The Migraine market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.
DelveInsight's "Migraine Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France)…
Migraine Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Therap …
Migraine Companies are Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others.
(Albany, USA) DelveInsight's "Migraine Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany,…
